Table 2.
Comparison of demographic, clinical, biochemical, and radiological features of patients grouped by evidence of choledocholithiasis on noninvasive imaging and presence or absence of ERCP-confirmed choledocholithiasis.
| Characteristics | Patients with pre-ERCP noninvasive imaging positive for choledocholithiasis (n = 156) |
Patients with pre-ERCP noninvasive imaging negative for choledocholithiasis (n = 114) |
||||
|---|---|---|---|---|---|---|
| ERCP-confirmed choledocholithiasis (n = 143) | Choledocholithiasis-negative ERCP (n = 13) | P-value | ERCP-confirmed choledocholithiasis (n = 87) | Choledocholithiasis-negative ERCP (n = 27) | P-value | |
| Age at ERCP (years), median (IQR) | 46 (33–57) | 36 (29–60) | 0.517 | 46 (31–56) | 57 (34–64) | 0.288 |
| Age >40 years, n (%) | 87 (60.8) | 5 (38.5) | 0.147 | 52 (59.8) | 18 (66.7) | 0.706 |
| Female, n (%) | 101 (70.6) | 6 (46.2) | 0.098 | 48 (55.2) | 13 (48.2) | 0.379 |
| Race/ethnicity, n (%) | 0.963 | 0.194 | ||||
| White | 10 (7.0) | 1 (7.7) | – | 4 (4.6) | 5 (18.5) | – |
| Hispanic/Latino | 112 (78.3) | 10 (76.9) | – | 61 (70.1) | 16 (59.3) | – |
| Black | 1 (0.7) | 0 | – | 2 (2.3) | 0 | – |
| Asian | 5 (3.5) | 0 | – | 2 (2.3) | 1 (3.7) | – |
| Other/unknown | 19 (13.3) | 2 (15.4) | – | 14 (16.1) | 5 (18.5) | – |
| BMI (kg/m2), median (IQR)b | 29.0 (25.0–34.0) | 28.1 (27.0–35.0) | 0.976 | 29.0 (26.0–34.0) | 29.3 (26.0–37.0) | 0.995 |
| BMI >30 kg/m2, n (%)b | 56 (39.2) | 4 (30.8) | 0.564 | 35 (40.2) | 12 (44.4) | 0.950 |
| Diabetes, n (%) | 21 (14.7) | 2 (15.4) | 0.914 | 9 (10.3) | 11 (40.7) | <0.001 |
| Fever, n (%) | 26 (18.2) | 3 (23.1) | 0.629 | 14 (16.1) | 8 (29.6) | 0.150 |
| Absence of classic cholelithiasis risk factors (BMI >30 kg/m2, female, age >40 years), n (%) | 9 (6.3) | 2 (15.4) | 0.217 | 7 (8.0) | 3 (11.1) | 0.716 |
| History of cholecystectomy, n (%) | 36 (25.2) | 3 (23.1) | 0.909 | 18 (20.7) | 6 (22.2) | 0.953 |
| Peak bilirubin pre-ERCP (mg/dL), median (IQR) | 3.1 (1.8–5.2) | 5.2 (3.5–6.0) | 0.150 | 4.5 (3.3–7.5) | 3.1 (1.9–5.8) | 0.064 |
| Noninvasive imaging, n (%) | ||||||
| Ultrasound | 143 (100.0) | 13 (100.0) | – | 87 (100.0) | 27 (100.0) | – |
| CT | 62 (43.4) | 4 (30.8) | 0.423 | 37 (42.5) | 13 (48.2) | 0.746 |
| MRCP | 58 (40.6) | 5 (38.5) | 0.944 | 6 (6.9) | 8 (29.6) | 0.002 |
| EUS performed, n (%) | 5 (3.5) | 0 | – | 7 (8.0) | 3 (12.0) | 0.602 |
| Maximum CBD diameter (mm) on noninvasive imaging, median (IQR)a | 10.0 (8.0–12.0) | 9.0 (6.0–10.0) | 0.058 | 7.0 (5.0–10.0) | 6.0 (4.0–9.0) | 0.616 |
Data are shown as n (%) or median (IQR).
Abbreviations: BMI, body mass index; CBD, common bile duct; CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound; MRCP, magnetic resonance cholangiopancreatography; IQR, interquartile range.
a
For patients who underwent more than one noninvasive imaging modality, the greatest maximum noninvasively-measured CBD diameter was used.
b
Six patients (2.2%) were missing BMI measurements.